Abstract

Background: Gender affirming hormone therapy (GAHT) may impact metabolic health and body composition in individuals with gender dysphoria.Aims and Objectives: The aim of this cross-sectional study was to investigate the effects of GAHT on metabolic health (HOMA2-IR and lipid parameters) and body composition [BIA (Bioelectrical impedance analysis)] in transgender individuals. They were divided into 4 groups: Group 1 (n=38) and Group 3 (n=12) consisted of treatment naïve transwomen and transmen while group 2 (n=7) and group 4 (n=22) consisted of transwomen and transmen on treatment for at least 6 months, respectively.Results: The groups 1 and 4 showed significant differences in FBG (fasting blood glucose), whole-body and subcutaneous fat and skeletal muscle percentages; (p<0.005) (cisgender setting). The visceral, subcutaneous fat and skeletal muscle percentages were also found to be different (p<0.01) (transgender setting). When groups 2 and 3 were compared, differences between TG, VLDL, subcutaneous fat and skeletal muscle percentages (cisgender setting) (p<0.05) were significant.Conclusions: Transmen on GAHT were found to have lower fasting glucose, skeletal muscle mass and higher whole-body and subcutaneous fat as compared to natal men. Transwomen on GAHT were found to have higher TG, VLDLC, skeletal muscle mass and lower subcutaneous fat compared to natal women.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call